(Q45273529)

11 December 2017

title

Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region (English)

1 reference

11 December 2017

1 reference

1 reference

Natsuizaka M

1

1 reference

11 December 2017

Hige S

2

1 reference

11 December 2017

Ono Y

3

1 reference

11 December 2017

Ogawa K

4

1 reference

11 December 2017

Nakanishi M

5

1 reference

11 December 2017

Chuma M

6

1 reference

11 December 2017

Yoshida S

7

1 reference

11 December 2017

Asaka M

8

1 reference

11 December 2017

publication date

1 March 2005

1 reference

Journal of Viral Hepatitis

11 December 2017

published in

1 reference

11 December 2017

volume

12

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

154-159

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00559.X

10.1111/J.1365-2893.2005.00559.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference